Gd biosciences national expansion

Global demand for the innovative heart disease blood test that detects individuals at risk of a heart attack who are missed by current methods prompts international expansion​.

​Irvine, California-based Global Discovery Biosciences (GD Biosciences), a biotechnology company dedicated in research and development of innovative technology to conquer some of the biggest challenges in healthcare, announced that it will expand availability of the PULS Cardiac Test to several additional countries.

GD Biosciences recently made the test available in the United Kingdom, but is pleased to announce the test will now be accessible to patients in Canada, India, Indonesia, China, United Arab Emirates and Qatar.

Already being widely adopted by U.S. physicians, the PULS Cardiac Test is a diagnostic blood test that detects the body's immune response to coronary artery injury in patients with no symptoms of heart disease (the Vulnerable Patient). The immune response frequently causes formation of unstable cardiac lesions in the coronary artery wall. The rupture of these lesions and formation of a blood clot at the site of the rupture is the most common cause of heart attacks. Identifying these vulnerable patients before they have a heart attack (Acute Coronary Syndrome) helps physicians improve patient care.

"The PULS Cardiac Test has become a critical tool for physicians to identify patients who may seem healthy. As one of my colleagues said, We tend to focus too much on the structural defects in heart disease, and not enough on the functional defects" said Douglas S. Harrington, M.D., CEO of GD Biosciences. "Damaged cholesterol causes injury to the coronary artery endothelium, but the body has the ability to repair this damage. In order to do so, it must receive a signal from the injury to activate the immune response and repair the damage. We detect the body's immune response to this injury and predict the likelihood of a heart attack."

Heart disease remains the leading cause of death and disability worldwide, but is 80% preventable with early detection and lifestyle modifications. A major issue for physicians is being able to accurately detect the disease, since most patients present with no signs or symptoms before a fatal or debilitating heart attack.

Numerous studies have shown 50% of heart attack victims have normal cholesterol levels. Recently, the American Heart Association's "Get with the Guidelines" revealed that over 70% of patients with a first Acute Coronary Syndrome (ACS) event were well within guideline targets for lipids.

The PULS Cardiac Test has been well received by the medical community as a "significant missing piece" of the clinical work up for its ability to identify cardiac lesions in asymptomatic "vulnerable" patients who may otherwise not know they are at risk of having a heart attack.

The test can predict the likelihood these patients will experience a Heart Attack (ACS event) within a 5-year period – allowing physicians to implement potentially life-saving prevention plans.

The PULS Test is an affordable, non-invasive blood test that is reimbursed by most insurance providers.

For more information and to request testing, visit www.pulstest.com.

About GD Biosciences

Global Discovery Biosciences (GD Biosciences) is a pioneer in the field of diagnostic medicine. The company works on the cutting edge of medical research, turns discoveries into innovative products and brings those products to the global marketplace.

The company works with advanced research teams to develop, manufacture and distribute innovative technology platforms to address the needs of the global disease burden. Its CLIA-certified and GMP laboratory performs a menu of clinically effective tests targeting key health issues. Our goal is to equip physicians with the tools they need to transform health care – one patient at a time.

About the PULS Cardiac Test

The PULS Cardiac Test is a simple blood test that uses breakthrough medical technology to identify individuals with active, yet undetected subclinical Coronary Heart Disease (CHD), who are at risk of experiencing a Heart Attack, and for whom early intervention can help. The test uses 9 clinically-significant protein biomarkers to measure the body's immune system response to arterial injury leading to the formation of unstable cardiac lesions – the cause of 75% of all Heart Attacks.

Check out our recent news coverage:
Fox News Special Report – Technology Helps Predict Heart Attacks
Travel Pulse – Could Blood Test Warn Pilots of Heart Attack Risk?
Times Colonist – Blood test can assess Heart Attack risk, conference told
Saskatoon Star Phoenix – New test for Heart Attack risk
The Province – Blood test can assess Heart Attack risk, Vancouver conference hears

MEDIA CONTACT:
Adam Farragut
PR Firm: The Publicity Agency
Email: Adam@Seligmultimedia.com
Phone: 813-708-1220 x7778
Website: www.thepublicityagency.com